Lowest Price Guaranteed From USD 4,799
Published
February 2022
Pages
481
View Count
17990
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The field of oral proteins / peptides has enormous opportunities. I believe the field will continue to grow at a rapid pace considering the healthy clinical pipeline of oral proteins / peptides.
-Chief Executive Officer, US based small-sized developer
The oral proteins and peptides market is estimated to be worth $1.4 billion in 2022 and and likely to grow to $8.3 billion by 2035. Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally administrable proteins / peptides. Interestingly, in the last decade, three orally administered protein / peptide-based therapies have been approved, namely Mycapssa® (2020), Trulance® (2017) and Linzess® (2012) across different geographies. The rising popularity of this upcoming class of therapeutics has led to the reformulation / development of oral protein / peptide-based product candidates for the treatment of a myriad of disease indications across multiple therapeutic areas (including but not limited to metabolic disorders, gastrointestinal disorders, autoimmune disorders). It is worth mentioning that oral administration is a favorable route for delivery of drugs to pediatric and geriatric patients, primarily due to its non-invasive nature. In addition, the ease of administration associated with the oral delivery method has been demonstrated increase treatment adherence to as well as reduce the risk of non-compliance.
Protein / peptide-based therapeutics have revolutionized the pharmaceutical landscape, this can be attributed to the wide applications and target specific nature of such interventions. However, oral formulations of protein / peptide-based drugs have been associated with several drawbacks, including poor bioavailability and drug decomposition in the gastrointestinal tract. In order to mitigate the aforementioned challenges, players engaged in this domain have conducted extensive research for the development of novel biological targets, thereby, strengthening their research pipelines. In addition, this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of developers. It is also worth mentioning that, over the last few years, the market has witnessed an active participation of big pharma players and substantial partnership activity. Given the ongoing research and development initiatives and an encouraging response to the already marketed drugs, the oral protein / peptide therapies market is poised to witness significant growth over the coming decade.
Several recent developments have taken place in the field of oral peptides and proteins. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘Oral Proteins and Peptides Market (4th Edition) by Target Disease Indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), Type of Molecule (protein and peptide), Technology Platforms, Biological Target (GC-C, insulin receptor, oxalate and others), Mechanism of Action (receptor stimulation, substrate degradation and others), Key Players, and Key Geographical Regions (North America, Europe, Asia-Pacific and RoW), 2022-2032’ report provides an extensive study on the current market landscape of orally administrable protein / peptide-based therapeutics, along with the future market potential. In addition, it provides an in-depth analysis, highlighting the market landscape of technology providers engaged in this domain. Amongst other elements, the report features:
One of the key objectives of this study was to understand the primary growth drivers and estimate the future size of the market based on various parameters, such as target consumer segments, likely adoption rates and expected pricing. We have also provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2032. In addition, we have provided the likely distribution of the market based on [A] target disease indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), [B] type of molecule (protein and peptide), [C] technology platforms, [D] biological target (GC-C, insulin receptor, oxalate, others), [E] mechanism of action (receptor stimulation, substrate degradation and others) [F] key players, and [G] key geographical regions (North America, Europe, Asia-Pacific and RoW). In order to account for the uncertainties associated with the growth of the oral proteins / peptides market and to add robustness to our model, we have provided three forecast scenarios, portraying conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Dinesh Srinivasan (Director, Anthera Pharmaceuticals), Stig K Hansen (Co-founder and CEO, Carmot Therapeutics), Terry Dyck (CEO, IGY Life Sciences and Technology) and Richard Franklin (CEO, Constant Therapeutics).
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of oral protein / peptide therapeutics market and its likely evolution in the short to mid-term, and long term.
Chapter 3 provides a comparison of the key characteristics of small molecules and large molecules / biologics. In addition, it includes a detailed discussion on proteins / peptides, highlighting their potential as therapeutic agents. Further, it features a discussion on the various routes of administration used for the delivery of drugs, with special focus on oral route. The chapter elaborates on the likely advantages and challenges associated with the oral route of administration. In addition, it includes a comprehensive discussion on the various approaches developed / under development for the effective oral delivery of proteins / peptides.
Chapter 4 includes information on over 125 programs for oral protein / peptide therapeutics that are either approved or being developed across different stages (commercial, clinical, preclinical or discovery stage) for the treatment of various indications. It features a comprehensive analysis of pipeline molecules, based on the type of molecule (protein or peptide), phase of development (commercial, clinical, preclinical or discovery stage), target therapeutic area(s), biological target, mechanism of action, number of amino acids and affiliated technology platform. In addition, the chapter includes information on drug developer(s), highlighting their year of establishment, company size, and location of headquarters.
Chapter 5 provides a detailed competitiveness analysis of oral protein / peptide therapy developers based on several relevant parameters, such as supplier power (in terms of years of experience and employee count), pipeline strength and phase of development.
Chapter 6 presents the key insights derived from the study. It features an in-depth analysis of the product pipeline and developer companies, featuring three schematic representations; these include [A] a four dimensional grid analysis, representing the distribution of oral proteins / peptides (on the basis of the type of molecule) across various target therapeutic areas and stages of development, [B] a logo landscape of companies involved in the development of oral protein / peptide-based drugs, distributed on the basis of phase of development of pipeline candidates and size of developer companies (small, mid-sized and large companies), and [C] a schematic world map representation, highlighting the most active geographies, in terms of the presence of various industry players engaged in the development of oral proteins / peptides
Chapter 7 provides a detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.
Chapter 8 highlights the potential target indications (segregated by therapeutic areas) that are currently the prime focus of companies developing oral proteins / peptides. These include metabolic disorders, gastrointestinal disorders and autoimmune disorders. The chapter also provides details on disease epidemiology, available diagnostic tests, and currently available treatment options for each indication and their likely side effects.
Chapter 9 contains detailed profiles of drugs that are either marketed or are in late stage (phase II / III and above) of development. Each profile features an overview of the drug, history of development, mechanism of action, dosage information (if available), manufacturing information (if available), current status of development, clinical trial information, key clinical trial results, historical sales (if marketed) and information on the developer.
Chapter 10 provides a review of oral proteins / peptides belonging other drug classes, namely cyclic peptides and PERTs, which are either commercialized or still under development. The chapter features detailed profiles of three popular orally administrable, therapeutic proteins / peptides (Minirin®, Sandimmune® and Sollpura®), which were discovered before 2000. Each profile contains an overview of the drug, history of development, chemical structure and mechanism of action, dosage information (if marketed), clinical trial information (if the product is currently under development), patent portfolio (if available) and information on the other commercially available treatment options for the disease indications for which each drug is approved.
Chapter 11 provides an overview of the market landscape of technology platforms available for the development of oral protein/ peptide therapeutics, including an analysis based on parameters, such as type of platform (drug formulation, drug development), compatible API types (peptide, protein and others), target therapeutics area, dosage form and status of development of products. In addition, the chapter also includes an analysis on the companies developing these platforms, based on year of their establishment, company size, and location of headquarters.
Chapter 12 features a 2X2 matrix, comparing product competitiveness and supplier power of the oral drug delivery technology platforms that are presently being utilized for the generation of oral proteins / peptides. The analysis takes into consideration several parameters, such as year of establishment, company size and development activity (number of drugs in both preclinical / clinical stages of development).
Chapter 13 features detailed profiles of some of the key technologies that have been used to develop oral protein / peptide therapeutics. Each profile contains details on the technology, including mechanism of action, pipeline molecules developed using the technology, its advantages and the various partnerships that were established related to the technology.
Chapter 14 presents details on various investments received by companies that are engaged in the development of oral protein / peptide therapeutics and / or associated delivery technologies. It also includes detailed analysis of the funding instances, based on several parameters, such as number of instances, amount invested, type of funding, focus aera, area of application, target therapeutic area, most active players and geographical analysis.
Chapter 15 provides a detailed analysis of the recent collaborations established since 2017. It includes analysis based on relevant parameters, such as year of partnership, type of agreement, focus area, type of partner and regional distribution of partnerships.
Chapter 16 presents a detailed review of more than 300 peer-reviewed, scientific articles related to research on oral protein / peptides, which have been published since 2017, including analysis based on parameters, such as year of publication, key focus area, type of molecule, popular keywords, key journals (in terms of number of articles published in this domain and impact factor of the journal) and affiliations.
Chapter 17 presents a detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active players (industry and non-industry) and regional distribution of trials.
Chapter 18 provides an in-depth analysis of the patents related to oral protein / peptides, filed / granted since 2017, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
Chapter 19 presents an analysis of big pharma players engaged in this domain, featuring a spider-web analysis based on several relevant parameters, such as number of pipeline candidates, partnership agreements and publications.
Chapter 20 presents an insightful market forecast analysis, highlighting the likely growth of oral protein / peptide therapeutics market, till 2032. In order to provide a detailed future outlook, our projections have been segmented across [A] target disease indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), [B] type of molecule (protein and peptide), [C] technology platforms, [D] biological target (GC-C, insulin receptor, oxalate, others), [E] mechanism of action (receptor stimulation, substrate degradation and others) [F] key players, and [G] key geographical regions (North America, Europe, Asia-Pacific and RoW).
Chapter 21 features a case study on the role of CMOs in the field of oral proteins / peptides. It provides details on the various factors that need to be considered while selecting the right CMO partner for the pharmaceutical companies. In addition, it includes a list of over 140 contract manufacturers that claim to have the necessary capabilities for protein / peptide manufacturing.
Chapter 22 provides an elaborate discussion on the various commercialization and lifecycle management strategies that have been adopted by drug developers engaged in this domain across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing stage.
Chapter 23 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the oral proteins / peptides market, under a comprehensive SWOT framework. The chapter also features a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall oral proteins / peptides market.
Chapter 24 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the oral protein / peptide therapeutics market.
Chapter 25 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Dinesh Srinivasan (Director, Anthera Pharmaceuticals), Stig K Hansen (Co-founder and CEO, Carmot Therapeutics), Terry Dyck (CEO, IGY Life Sciences and Technology) and Richard Franklin (CEO, Constant Therapeutics).
Chapter 26 is an appendix, which provides tabulated information on the historical developments.
Chapter 27 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 28 is an appendix, which contains a list of companies and organizations.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Comparison of Biologics and Small Molecules
3.3. Introduction to Proteins
3.3.1. Protein Structure
3.3.2. Classification of Proteins
3.4. Introduction to Peptides
3.4.1. Peptide Structure
3.4.2. Classification of Peptides
3.4.2.1. Synthetic Peptides
3.4.2.2. Recombinant Peptides
3.5. Routes of Administration for Proteins / Peptides
3.5.1. Parenteral Administration
3.5.1.1. Intramuscular Route
3.5.1.2. Intravenous Route
3.5.1.3. Subcutaneous Route
3.5.2. Non-Parenteral Administration
3.5.2.1. Buccal / Sublingual Route
3.5.2.2. Intranasal Route
3.5.2.3. Oral Route
3.5.2.4. Ocular Route
3.5.2.5. Pulmonary Route / Inhalation
3.5.2.6. Rectal Route
3.5.2.7. Transdermal Route
3.5.3. Comparison of Different Routes of Drug Administration
3.6. Oral Delivery of Proteins / Peptides
3.6.1. Key Advantages of Oral Administration
3.6.2. Key Challenges Associated with Oral Administration
3.7. Approaches Used for Structural and Bioavailability Enhancement
3.7.1. Absorption Enhancers
3.7.2. Chemical Modification
3.7.2.1 Pro Drug Approach
3.7.3. Enzyme Inhibitors
3.7.4. Muco-Adhesive Polymeric Systems
3.7.5. Nanoparticular Delivery Systems
3.7.5.1. Liposomes
3.7.5.2. Nanoparticles / Microparticles
3.7.6. PEGylation
3.8. Concluding Remarks
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Oral Proteins / Peptide Therapeutics: Market Landscape
4.2.1. Analysis by Type of Molecule
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Target Therapeutic Area
4.2.4. Analysis by Biological Target
4.2.5. Analysis by Mechanism of Action
4.2.6. Analysis by Phase of Development and Mechanism of Action
4.2.7. Analysis by Number of Amino Acids
4.2.8. Key Drug Development Platforms: Analysis by Number of Products
4.3. Oral Proteins / Peptide Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Most Active Players: Analysis by Number of Pipeline Candidates
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Parameters
5.3. Oral Protein / Peptide Therapy Developers: Competitiveness Analysis
6. KEY INSIGHTS
6.1. Chapter Overview
6.2. Oral Proteins / Peptides Pipeline: Grid Analysis
6.3. Oral Proteins / Peptides Pipeline: Developer Landscape
6.4. Oral Proteins / Peptides Pipeline: Regional Landscape (Industry Players)
7. KOL ANALYSIS
7.1. Chapter Overview
7.2. Oral Protein / Peptide Therapeutics: List of Key Opinion Leaders
7.2.1. Analysis by Type of Current Organization
7.2.2. Analysis by Geography
7.2.2.1. Analysis by Region (Continent-wise)
7.2.2.2. Analysis by Region (Country-wise)
7.2.3. Analysis by Number of Investigators and Current Organization
7.2.4. Analysis by Qualification of KOL
7.2.5. Comparison of KOL Activeness v/s Strength (Scatter Plot)
7.2.6. Comparison of Roots Analysis Score v/s Third Party Score
7.2.7. Prominent Players: Comparison of Roots Analysis Score v/s Third Party Score
7.2.8. Most Active Key Opinion Leaders: Comparison of Professional Network v/s Academic Strength
8. KEY THERAPEUTIC AREAS
8.1. Chapter Overview
8.2. Metabolic Disorders
8.2.1. Diabetes
8.2.1.1. Disease Description
8.2.1.2. Associated Health Risks / Complications
8.2.1.3. Epidemiology
8.2.1.4. Disease Diagnosis
8.2.1.5. Current Treatment Options
8.2.1.5.1. Insulin Therapies
8.2.1.5.2. Non-Insulin Therapies
8.2.1.6. Side Effects of Current Treatment Options
8.2.1.7. Oral Proteins / Peptides for Diabetes
8.2.2. Obesity
8.2.2.1. Disease Description
8.2.2.2. Epidemiology
8.2.2.3. Current Treatment Options
8.2.2.4. Side Effects of Current Treatment Options
8.2.2.5. Oral Proteins / Peptides for Obesity
8.2.3. Non-alcoholic Steatohepatitis (NASH)
8.2.3.1. Disease Description
8.2.3.2. Epidemiology
8.2.3.3. Current Treatment Options
8.2.3.4. Oral Proteins / Peptides for NASH
8.3. Digestive and Gastrointestinal Disorders
8.3.1. Ulcerative Colitis
8.3.1.1. Disease Description
8.3.1.2. Epidemiology
8.3.1.3. Current Treatment Options
8.3.1.4. Side Effects of Current Treatment Options
8.3.1.5. Oral Proteins / Peptides for Ulcerative Colitis
8.3.2. Crohn’s Disease
8.3.2.1. Disease Description
8.3.2.2. Epidemiology
8.3.2.3. Current Treatment Options
8.3.2.4. Side Effects of Current Treatment Options
8.3.2.5. Oral Proteins / Peptides for Crohn’s Disease
8.4. Infectious Diseases
8.4.1. C. difficile Infections (CDIs)
8.4.1.1. Disease Description
8.4.1.2. Epidemiology
8.4.1.3. Disease Diagnosis
8.4.1.4. Current Treatment Options
8.4.1.5. Side Effects of Current Treatment Options
8.4.1.6. Oral Proteins / Peptides for CDIs
8.5. Autoimmune Disorders
8.5.1. Celiac Disease
8.5.1.1. Disease Description
8.5.1.2. Epidemiology
8.5.1.3. Disease Diagnosis
8.5.1.4. Current Treatment Options
8.5.1.5. Oral Proteins / Peptides for Celiac Disease
8.6. Hormonal Disorders
8.6.1. Acromegaly
8.6.1.1. Disease Description
8.6.1.2. Epidemiology
8.6.1.3. Disease Diagnosis
8.6.1.4. Current Treatment Options
8.6.1.5. Side Effects of Current Treatment Options
8.6.1.6. Oral Proteins / Peptides for Acromegaly
8.7. Bone Disorders
8.7.1. Osteoporosis
8.7.1.1. Disease Description
8.7.1.2. Epidemiology
8.7.1.3. Disease Diagnosis
8.7.1.4. Current Treatment Options
8.7.1.5. Side Effects of Current Treatment Options
8.7.1.6. Oral Proteins / Peptides for Osteoporosis
9. MARKETED AND LATE-STAGE DRUG PROFILES
9.1. Chapter Overview
9.2. Linzess® / Constella® / Linaclotide (Ironwood Pharmaceuticals)
9.2.1. Drug Overview
9.2.2. History of Development
9.2.3. Mechanism of Action
9.2.4. Dosage Form, Treatment Regimen and Price
9.2.5. Manufacturing Information
9.2.6. Current Status of Development
9.2.7. Clinical Studies
9.2.8. Key Clinical Trial Results
9.2.9. Historical Sales
9.2.10. Developer Overview
9.3. Trulance® / Plecanatide (Synergy Pharmaceuticals)
9.3.1. Drug Overview
9.3.2. History of Development
9.3.3. Mechanism of Action
9.3.4. Dosage Form, Treatment Regimen and Price
9.3.5. Manufacturing Information
9.3.6. Current Status of Development
9.3.7. Clinical Studies
9.3.8. Key Clinical Trial Results
9.3.9. Historical Sales
9.3.10. Developer Overview
9.4. TBRIA™ / Oral Calcitonin (Tarsa Therapeutics / Enteris BioPharma)
9.4.1. Drug Overview
9.4.2. History of Development
9.4.3. Mechanism of Action
9.4.4. Manufacturing Information
9.4.5. Current Status of Development
9.4.6. Clinical Studies
9.4.7. Key Clinical Trial Results
9.4.8. Developer Overview
9.5. Mycapssa® / (Chiasma Pharma)
9.5.1. Drug Overview
9.5.2. History of Development
9.5.3. Mechanism of Action
9.5.4. Manufacturing Information
9.5.5. Current Status of Development
9.5.6. Clinical Studies
9.5.7. Key Clinical Trial Results
9.5.8. Developer Overview
9.6. ALLN-177 (Allena Pharmaceuticals)
9.7. INN-202 (9 Meters Biopharma)
9.8. ORMD-0801 (Oramed Pharmaceuticals)
9.9. IN-105 (Biocon)
9.10. Oral HDV Insulin (Diasome Pharmaceuticals)
10. CASE STUDIES: MINIRIN®, SANDIMMUNE® AND SOLLPURA®
10.1. Chapter Overview
10.2. Minirin® / DDAVP (Ferring Pharmaceuticals)
10.2.1. Drug Overview
10.2.2. History of Development
10.2.3. Chemical Structure and Mechanism of Action
10.2.4. Dosage Form, Treatment Regimen and Price
10.2.5. Patent Portfolio
10.2.6. Competitive Landscape
10.3. Sandimmune® / Neoral® (Novartis)
10.3.1. Drug Overview
10.3.2. History of Development
10.3.3. Mechanism of Action
10.3.4. Dosage Form, Treatment Regimen and Price
10.3.5. Patent Portfolio
10.3.6. Competitive Landscape
10.4. Sollpura® / Liprotamase (Anthera Pharmaceuticals)
10.4.1. Drug Overview
10.4.2. History of Development
10.4.3. Chemical Structure and Mechanism of Action
10.4.4. Current Status of Development
10.4.5. Clinical Studies
10.4.6. Competitive Landscape
11. ORAL PROTEIN / PEPTIDE DEVELOPMENT TECHNOLOGIES: MARKET LANDSCAPE
11.1. Chapter Overview
11.2. Oral Protein / Peptide Development Technologies: Market Landscape
11.2.1. Analysis by Type of Technology
11.2.2. Analysis by Compatible API Types
11.2.3. Analysis by Target Therapeutic Area
11.2.4. Analysis by Dosage Form
11.2.5. Analysis by Status of Development of Products
11.3. Oral Protein / Peptide Development Technologies: Developer Landscape
11.3.1 Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3 Analysis by Location of Headquarters
11.3.4. Analysis by Company Size and Location of Headquarters
12. PRODUCT COMPETITIVENESS ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Product Competitiveness Analysis: Key Technologies
13. ORAL DRUG DELIVERY TECHNOLOGY PLATFORMS
13.1. Chapter Overview
13.2. Oral Drug Delivery: List of Technology Platforms
13.3. Technology Profiles
13.3.1. Axcess™ Oral Drug Delivery Technology (Proxima Concepts)
13.3.1.1. Developer Overview
13.3.1.2. Technology Overview
13.3.1.3. Drug Delivery Mechanism
13.3.1.4. Key Advantages
13.3.1.5. Oral Proteins / Peptides Pipeline
13.3.1.6. Collaborations
13.3.2. Eligen™ Technology (Emisphere Technologies)
13.3.2.1. Developer Overview
13.3.2.2. Technology Overview
13.3.2.3. Drug Delivery Mechanism
13.3.2.4. Key Advantages
13.3.2.5. Oral Proteins / Peptides Pipeline
13.3.2.6. Collaborations
13.3.3. Entera Technology (Entera Bio)
13.3.3.1. Developer Overview
13.3.3.2. Technology Overview
13.3.3.3. Drug Delivery Mechanism
13.3.3.4. Key Advantages
13.3.3.5. Oral Proteins / Peptides Pipeline
13.3.4. NTRA Oral Delivery Technology (Nutrinia)
13.3.4.1. Developer Overview
13.3.4.2. Technology Overview
13.3.4.3. Drug Delivery Mechanism
13.3.4.4. Key Advantages
13.3.4.5. Oral Proteins / Peptides Pipeline
13.3.5. Peptelligence® Technology (Enteris BioPharma)
13.3.5.1. Developer Overview
13.3.5.2. Technology Overview
13.3.5.3. Drug Delivery Mechanism
13.3.5.4. Key Advantages
13.3.5.5. Oral Proteins / Peptides Pipeline
13.3.5.6. Collaborations
13.3.6. Protein Oral Delivery (POD™) Technology (Oramed Pharmaceuticals)
13.3.6.1. Developer Overview
13.3.6.2. Technology Overview
13.3.6.3. Drug Delivery Mechanism
13.3.6.4. Key Advantages
13.3.6.5. Oral Proteins / Peptides Pipeline
13.3.7. Transient Permeability Enhancer (TPE®) Technology (Chiasma Pharma)
13.3.7.1. Developer Overview
13.3.7.2. Technology Overview
13.3.7.3. Drug Delivery Mechanism
13.3.7.4. Key Advantages
13.3.7.5. Oral Proteins / Peptides Pipeline
13.3.8. Uroguanylin Analogue Technology (Synergy Pharmaceuticals)
13.3.8.1. Developer Overview
13.3.8.2. Technology Overview
13.3.8.3. Drug Delivery Mechanism
13.3.8.4. Key Advantages
13.3.8.5. Oral Proteins / Peptides Pipeline
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. Oral Proteins / Peptides: Funding and Investment Analysis
14.3.1. Analysis by Cumulative Number of Funding Instances
14.3.2. Analysis by Cumulative Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Year, Type of Funding and Amount Invested
14.3.5. Analysis by Focus Area
14.3.6. Analysis by Area of Application
14.3.7. Analysis by Target Therapeutic Area
14.3.8. Analysis by Geography
14.3.9. Most Active Players: Analysis by Number of Instances
14.3.10. Most Active Players: Analysis by Amount Invested
14.4. Concluding Remarks
15. RECENT COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Oral Proteins / Peptides: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Area of Application
15.3.4. Analysis by Type of Partner
15.3.5. Analysis by Focus Area
15.3.6. Analysis by Target Therapeutic Area
15.3.7. Most Active Players: Analysis by Number of Partnerships
15.3.8. Analysis by Geography
15.3.9. Intercontinental and Intracontinental Agreements
16. PUBLICATION ANALYSIS
16.1. Chapter Overview
16.2. Oral Proteins / Peptides: List of Publications
16.2.1. Analysis by Year of Publication
16.2.2. Analysis by Type of Molecule
16.2.3. Analysis by Target Therapeutic Area
16.2.4. Word Cloud of Study Titles
16.2.5. Most Prominent Journals: Analysis by Number of Publications
16.2.6. Most Prominent Authors: Analysis by Number of Publications
17. CLINICAL TRIAL ANALYSIS
17.1. Chapter Overview
17.2. Scope and Methodology
17.3. Oral Protein / Peptide Therapeutics: Clinical Trial Analysis
17.3.1. Analysis by Trial Registration Year
17.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
17.3.3. Analysis by Trial Status
17.3.4. Analysis by Trial Phase
17.3.5. Analysis by Trial Registration Year and Trial Status
17.3.6. Analysis by Enrolled Patient Population and Trial Phase
17.3.7. Analysis by Type of Sponsor / Collaborator
17.3.8. Analysis by Patient Segment
17.3.9. Analysis by Target Therapeutic Area
17.3.10. Analysis by Study Design
17.3.11. Most Active Players: Analysis by Number of Registered Trials
17.3.12. Analysis by Number of Trials and Geographical Location
17.3.13. Analysis by Number of Trials, Trial Status and Geographical Location
17.3.14. Analysis by Enrolled Patient Population and Trial Status
18. PATENT ANALYSIS
18.1. Chapter Overview
18.2. Scope and Methodology
18.3. Oral Protein / Peptide Therapeutics: Patent Analysis
18.3.1. Analysis by Publication Year
18.3.2. Analysis by Patent Jurisdiction
18.3.3. Analysis by Legal Status
18.3.4. Analysis by CPC Symbols
18.3.5. Emerging Focus Areas
18.3.6. Analysis by Type of Applicant
18.3.7. Leading Players: Analysis by Number of Patents
18.3.8. Key Inventors: Analysis by Number of Patents
18.4. Oral Protein / Peptide Therapeutics: Patent Benchmarking Analysis
18.4.1. Analysis by Patent Characteristics
18.4.2. Analysis by Geography
18.5. Oral Protein / Peptide Therapeutics: Patent Valuation Analysis
19. BIG PHARMA ANALYSIS
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Oral Protein / Peptide Therapeutics: Big Pharma Initiatives
19.3.1. Analysis by Target Therapeutic Area
19.3.2. Analysis by Type of Initiative
19.3.3. Big Pharma Players: Benchmarking Analysis
20. MARKET FORECAST AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Scope and Limitations
20.3. Forecast Methodology
20.4. Global Oral Protein / Peptide Therapy Market, 2022-2032
20.4.1. Oral Protein / Peptide Therapy Market: Distribution by Target Disease Indication
20.4.2. Oral Protein / Peptide Therapy Market: Distribution by Type of Molecule
20.4.3. Oral Protein / Peptide Therapy Market: Distribution by Technology Platform
20.4.4. Oral Protein / Peptide Therapy Market: Distribution by Biological Target
20.4.5. Oral Protein / Peptide Therapy Market: Distribution by Mechanism of Action
20.4.6. Oral Protein / Peptide Therapy Market: Distribution by Key Players
20.4.7. Oral Protein / Peptide Therapy Market: Distribution by Geography
20.5. Oral Proteins / Peptides Market: Product-wise Sales Forecasts
20.5.1. Linzess® / Constella® / Linaclotide (Ironwood Pharmaceuticals)
20.5.1.1. Target Patient Population
20.5.1.2. Sales Forecast
20.5.2. Trulance® / Plecanatide (Synergy Pharmaceuticals)
20.5.2.1. Target Patient Population
20.5.2.2. Sales Forecast
20.5.3. Mycapssa® / Octreolin (Chiasma Pharma)
20.5.3.1. Target Patient Population
20.5.3.2. Sales Forecast
20.5.4. ALLN-177 (Allena Pharmaceuticals)
20.5.4.1. Target Patient Population
20.5.4.2. Sales Forecast
20.5.5. Larazotide INN-202 (Innovate Biopharmaceuticals)
20.5.5.1. Target Patient Population
20.5.5.2. Sales Forecast
20.5.6. Oral HDV Insulin (Diasome Pharmaceuticals)
20.5.6.1. Target Patient Population
20.5.6.2. Sales Forecast
20.5.7. ORMD-0801 (Oramed Pharmaceuticals)
20.5.7.1. Target Patient Population
20.5.7.2. Sales Forecast
20.5.8. IN-105 / Insulin Tregopil (Biocon)
20.5.8.1. Target Patient Population
20.5.8.2. Sales Forecast
21. CASE STUDY: PROTEIN / PEPTIDE MANUFACTURING
21.1. Chapter Overview
21.2. Key Steps Involved in Protein / Peptide Manufacturing
21.3. Challenges Associated with Protein / Peptide Manufacturing
21.4. Current Scenario of Protein / Peptide Manufacturing
21.5. Growing Demand for Contract Manufacturing
21.5.1. Selecting A Suitable CMO Partner
21.5.2. Protein / Peptide CMOs: Market Landscape
21.5.2.1. Analysis by Year of Establishment
21.5.2.2. Analysis by Company Size
21.5.2.3. Analysis by Location of Headquarters
22. KEY COMMERCIALIZATION / LIFECYCLE MANAGEMENT STRATEGIES
22.1. Successful Drug Launch Strategy: ROOTS Framework
22.2. Successful Drug Launch Strategy: Product Differentiation
22.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
22.4. Key Commercialization / Lifecycle Management Strategies Adopted by Companies Focused on Oral Protein / Peptide Therapeutics
22.4.1. Strategies Adopted Before Therapy Approval
22.5. Strategies Adopted During / Post Therapy Approval
22.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)
23. SWOT ANALYSIS
23.1. Chapter Overview
23.2. Comparison of SWOT Factors
24. CONCLUSION
24.1 Chapter Overview
25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Anthera Pharmaceuticals
25.2.1. Company Snapshot
25.2.2. Interview Transcript: Dinesh Srinivasan, Director
25.3. Carmot Therapeutics
25.3.1. Company Snapshot
25.3.2. Interview Transcript: Stig K Hansen, CEO
25.4. IGY Life Sciences and Technology
25.4.1. Company Snapshot
25.4.2. Interview Transcript: Terry Dyck, President and CEO
25.5. Constant Therapeutics
25.5.1. Company Snapshot
25.5.2. Interview Transcript: Richard Franklin, CEO
26. APPENDIX 1: RECENT DEVELOPMENTS
27. APPENDIX 2: TABULATED DATA
28. APPENDIX 3: LIST OF COMPANIES
Figure 2.1 Executive Summary: Pipeline Overview
Figure 2.2 Executive Summary: KOL Analysis
Figure 2.3 Executive Summary: Drug Development Technology Providers Landscape
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Partnerships and Collaborations
Figure 2.6 Executive Summary: Publication Analysis
Figure 2.7 Executive Summary: Clinical Trial Analysis
Figure 2.8 Executive Summary: Patent Analysis
Figure 2.9 Executive Summary: Big Pharma Analysis
Figure 2.10 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Comparison of Key Characteristics of Biologics and Small Molecules
Figure 3.2 Classification of Proteins
Figure 3.3 Routes of Administration for Proteins / Peptides
Figure 3.4 Drug Delivery: Distribution by Route of Administration
Figure 3.5 Mechanisms of Drug Transport through the Intestinal Epithelium
Figure 3.6 Mechanisms of Drug Transport through the Intestinal Epithelium via Attachment of Absorption Enhancers
Figure 3.7 Mechanisms of Drug Transport through the Intestinal Epithelium via Pro Drug Approach
Figure 3.8 Mechanisms of Drug Transport through the Intestinal Epithelium via Attachment of Enzyme Inhibitors
Figure 4.1 Oral Protein / Peptide Therapeutics: Distribution by Type of Molecule
Figure 4.2 Oral Protein / Peptide Therapeutics: Distribution by Phase of Development
Figure 4.3 Oral Protein / Peptide Therapeutics: Distribution by Target Therapeutic Area
Figure 4.4 Oral Protein / Peptide Therapeutics: Distribution by Biological Target
Figure 4.5 Oral Protein / Peptide Therapeutics: Distribution by Mechanism of Action
Figure 4.6 Oral Protein / Peptide Therapeutics: Distribution by Phase of Development and Mechanism of Action
Figure 4.7 Oral Protein / Peptide Therapeutics: Distribution by Number of Amino Acids
Figure 4.8 Key Drug Development Platforms: Distribution by Number of Products
Figure 4.9 Oral Protein / Peptide Therapeutics Developers: Distribution by Year of Establishment
Figure 4.10 Oral Protein / Peptide Therapeutics Developers: Distribution by Company Size
Figure 4.11 Oral Protein / Peptide Therapeutics Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.12 Oral Protein / Peptide Therapeutics Developers: Distribution by Location of Headquarters (Country-wise)
Figure 4.13 Oral Protein / Peptide Therapeutics Developers: Distribution by Company Size and Location of Headquarters (Region-wise)
Figure 4.14 Most Active Players: Distribution by Number of Pipeline Candidates
Figure 4.15 Most Active Players: Distribution by Phase of Development
Figure 5.1 Oral Protein / Peptide Therapy Developers: Competitiveness Analysis
Figure 6.1 Oral Proteins / Peptides: Distribution by Therapeutic Area, Type of Molecule and Phase of Development (Grid Analysis)
Figure 6.2 Oral Proteins / Peptides Developer Landscape: Distribution by Company Size and Phase of Development
Figure 6.3 Oral Proteins / Peptides Regional Landscape (Industry Players): Distribution by Location of Headquarters and Pipeline Strength
Figure 7.1 KOL Analysis: Distribution by Type of Current Organization
Figure 7.2 KOL Analysis: Distribution by Geography
Figure 7.3 KOL Analysis: Distribution by Region (Continent-wise)
Figure 7.4 KOL Analysis: Distribution by Region (Country-wise)
Figure 7.5 KOL Analysis: Distribution by Number of Investigators and Current Organization
Figure 7.6 KOL Analysis: Distribution by Qualification of KOL
Figure 7.7 Comparison of KOL Activeness v/s Strength (Scatter Plot)
Figure 7.8 Comparison of Roots Analysis Score v/s Third Party Score
Figure 7.9 Prominent Players: Comparison of Roots Analysis Score v/s Third Party Score
Figure 7.10 Most Active Key Opinion Leaders: Comparison of Professional Network v/s Academic Strength
Figure 8.1 Diabetes: Diagnostic Limits for Plasma Glucose Levels
Figure 8.2 Non-Insulin Therapies for Diabetes
Figure 9.1 Linzess®: History of Development
Figure 9.2 Linzess®: Historical Sales, 2015-2020 (USD Million)
Figure 9.3 Trulance®: History of Development
Figure 9.4 TBRIA®: History of Development
Figure 9.5 Mycapssa®: History of Development
Figure 11.1 Oral Protein / Peptide Development Technologies: Distribution by Type of Technology
Figure 11.2 Oral Protein / Peptide Development Technologies: Distribution by Compatible API Types
Figure 11.3 Oral Protein / Peptide Development Technologies: Distribution by Type of Technology and Compatible API Types
Figure 11.4 Oral Protein / Peptide Development Technologies: Distribution by Target Therapeutic Area
Figure 11.5 Oral Protein / Peptide Development Technologies: Distribution by Dosage Form
Figure 11.6 Oral Protein / Peptide Development Technologies: Distribution by Status of Development of Products
Figure 11.7 Oral Protein / Peptide Development Technology Developers: Distribution by Year of Establishment
Figure 11.8 Oral Protein / Peptide Development Technology Developers: Distribution by Company Size
Figure 11.9 Oral Protein / Peptide Development Technology Developers: Distribution by Location of Headquarters (Region-wise)
Figure 11.10 Oral Protein / Peptide Development Technology Developers: Distribution by Location of Headquarters (Country-wise)
Figure 11.11 Oral Protein / Peptide Development Technology Developers: Distribution by Company Size and Location of Headquarters (Region-wise)
Figure 12.1 Oral Protein / Peptide Development Technologies: Competitiveness Analysis
Figure 14.1 Funding and Investment Analysis: Cumulative Distribution by Number of Funding Instances
Figure 14.2 Funding and Investment Analysis: Cumulative Amount Invested (USD Million)
Figure 14.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 14.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 14.5 Funding and Investment Analysis: Summary of Amount Invested
Figure 14.6 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested (USD Million)
Figure 14.7 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area (USD Million)
Figure 14.8 Funding and Investment Analysis: Distribution of Amount Invested by Area of Application (USD Million)
Figure 14.9 Funding and Investment Analysis: Distribution of Number of Instances by Target Therapeutic Area
Figure 14.10 Funding and Investment Analysis: Distribution of Amount Invested by Target Therapeutic Area (USD Million)
Figure 14.11 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 14.12 Funding and Investment Analysis: Regional Distribution by Total Amount Invested (USD Million)
Figure 14.13 Most Active Players: Distribution by Number of Instances
Figure 14.14 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 14.15 Funding and Investment Analysis: Concluding Remarks
Figure 15.1 Partnerships and Collaborations: Cumulative Year-wise Distribution
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Agreement
Figure 15.3 Partnerships and Collaborations: Distribution by Area of Application
Figure 15.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Agreement
Figure 15.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 15.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 15.7 Partnerships and Collaborations: Distribution by Focus Area
Figure 15.8 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 15.9 Most Active Players: Distribution by Number of Partnerships
Figure 15.10 Partnerships and Collaborations: Geographical Distribution
Figure 15.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 16.1 Publication Analysis: Cumulative Year-wise Trend
Figure 16.2 Publication Analysis: Distribution by Type of Molecule
Figure 16.3 Publication Analysis: Distribution by Target Therapeutic Area
Figure 16.4 Publication Analysis: Word Cloud of Study Titles
Figure 16.5 Most Prominent Journals: Distribution by Number of Publications
Figure 16.6 Most Prominent Authors: Distribution by Number of Publications
Figure 17.1 Clinical Trial Analysis: Methodology
Figure 17.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 17.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 17.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 17.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 17.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 17.7 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Phase
Figure 17.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 17.9 Clinical Trial Analysis: Distribution by Patient Segment
Figure 17.10 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 17.11 Clinical Trial Analysis: Distribution by Study Design
Figure 17.12 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 17.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 17.14 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geographical Location
Figure 17.15 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geographical Location
Figure 17.16 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Status
Figure 18.1 Patent Analysis: Distribution by Type of Patent
Figure 18.2 Patent Analysis: Cumulative Distribution by Publication Year
Figure 18.3 Patent Analysis: Distribution by Patent Jurisdiction
Figure 18.4 Patent Analysis: Distribution by Legal Status
Figure 18.5 Patent Analysis: Distribution by CPC Symbols
Figure 18.6 Patent Analysis: Emerging Focus Areas
Figure 18.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Figure 18.8 Leading Industry Players: Distribution by Number of Patents
Figure 18.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 18.10 Leading Industry Players: Distribution by International Patents
Figure 18.11 Leading Patent Assignees: Distribution by Number of Patents
Figure 18.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Figure 18.13 Patent Analysis: Distribution of Patents by Age
Figure 18.14 Oral Protein / Peptide Therapeutics: Patent Valuation
Figure 19.1 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Figure 19.2 Big Pharma Players: Benchmarking Analysis
Figure 20.1 Global Oral Protein / Peptide Therapy Market, 2022-2032 (USD Million)
Figure 20.2 Oral Protein / Peptide Therapy Market: Distribution by Target Disease Indication, 2022, 2025 and 2032 (USD Million)
Figure 20.3 Oral Proteins / Peptide Therapy Market: Distribution by Type of Molecule, 2022, 2025 and 2032 (USD Million)
Figure 20.4 Oral Proteins / Peptide Therapy Market: Distribution by Technology Platform, 2022, 2025 and 2032 (USD Million)
Figure 20.5 Oral Proteins / Peptide Therapy Market: Distribution by Biological Target, 2022, 2025 and 2032 (USD Million)
Figure 20.6 Oral Proteins / Peptide Therapy Market: Distribution by Mechanism of Action, 2022, 2025 and 2032 (USD Million)
Figure 20.7 Oral Proteins / Peptide Therapy Market: Distribution by Key Players, 2022, 2025 and 2032 (USD Million)
Figure 20.8 Oral Protein / Peptide Therapy Market: Distribution by Geography 2022 and 2032 (USD Million)
Figure 20.9 Linzess® (Ironwood Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Figure 20.10 Trulance® (Bausch Health Sciences): Estimated Sales, 2022-2032 (USD Million)
Figure 20.11 Mycapssa® (Chiasma): Estimated Sales, 2022-2032 (USD Million)
Figure 20.12 ALLN-177 (Allena Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Figure 20.13 INN-202 (9 Meters Biopharma): Estimated Sales, 2022-2032 (USD Million)
Figure 20.14 Oral HDV Insulin (Diasome Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Figure 20.15 ORMD-0801 (Oramed Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Figure 20.16 IN-105 (Biocon): Estimated Sales, 2022-2032 (USD Million)
Figure 21.1 Key Steps Involved in the Manufacturing of Biologics
Figure 21.2 Approval Trend for Small Molecule and Large Molecule Drugs (2005-2017)
Figure 21.3 Factors for Selecting a CMO Partner
Figure 21.4 Protein / Peptide Manufacturers: Distribution by Year of Establishment
Figure 21.5 Protein / Peptide Manufacturers: Distribution by Company Size
Figure 21.6 Protein / Peptide Manufacturers: Distribution by Location of Headquarters
Figure 22.1 Key Commercialization Strategies: Harvey Ball Analysis
Figure 22.2 Successful Drug Launch Strategy: ROOTS Framework
Figure 22.3 Successful Drug Launch Strategy: Product Differentiation
Figure 22.4 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
Figure 22.5 Harvey Ball Analysis: Commercialization Strategies Adopted by Oral Protein / Peptide Therapy Developers
Figure 23.1 Oral Proteins / Peptides SWOT Analysis: Overview
Figure 23.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 24.1 Concluding Remarks: Pipeline Overview
Figure 24.2 Concluding Remarks: KOL Analysis
Figure 24.3 Concluding Remarks: Drug Development Technology Providers Landscape
Figure 24.4 Concluding Remarks: Funding and Investment Analysis
Figure 24.5 Concluding Remarks: Partnerships and Collaborations
Figure 24.6 Concluding Remarks: Publication Analysis
Figure 24.7 Concluding Remarks: Clinical Trial Analysis
Figure 24.8 Concluding Remarks: Patent Analysis
Figure 24.9 Concluding Remarks: Big Pharma Analysis
Figure 24.10 Concluding Remarks: Market Forecast and Opportunity Analysis
Table 3.1 Comparison of Key Routes of Delivery
Table 4.1 Oral Proteins / Peptide Therapeutics: Drug Pipeline
Table 4.2 Oral Proteins / Peptide Therapeutics: Information on Disease Indication, Target Therapeutic Area, Biological Target and Mechanism of Action
Table 4.3 Oral Proteins / Peptide Therapeutics: Information on Number of Amino Acids and Platform Used for Development
Table 4.4 Oral Proteins / Peptide Therapy Developers: Information on Year of Establishment, Employee Count, Company Size and Headquarters
Table 4.5 Oral Proteins / Peptide Therapeutics: Other Drugs
Table 7.1 Oral Proteins / Peptide Therapeutics: Principal Investigators
Table 8.1 Diabetes: Current Treatment Options
Table 8.2 Diabetes: Side Effects of Current Treatment Options
Table 8.3 Diabetes: Oral Proteins / Peptides Pipeline
Table 8.4 Obesity: Side Effects of Current Treatment Options
Table 8.5 Obesity: Oral Proteins / Peptides Pipeline
Table 8.6 NASH: Oral Proteins / Peptides Pipeline
Table 8.7 Ulcerative Colitis: Current Treatment Options
Table 8.8 Ulcerative Colitis: Side Effects of Current Treatment Options
Table 8.9 Ulcerative Colitis: Oral Proteins / Peptides Pipeline
Table 8.10 Crohn’s Disease: Current Treatment Options
Table 8.11 Crohn’s Disease: Side Effects of Current Treatment Options
Table 8.12 Crohn’s Disease: Oral Proteins / Peptides Pipeline
Table 8.13 CDIs: Diagnostic Testing
Table 8.14 CDIs: Severity Scoring System and Treatment Options
Table 8.15 CDIs: Side Effects of Current Treatment Options
Table 8.16 CDIs: Oral Proteins / Peptides Pipeline
Table 8.17 Celiac Disease: Oral Proteins / Peptides Pipeline
Table 8.18 Acromegaly: Current Treatment Options
Table 8.19 Acromegaly: Side Effects of Current Treatment Options
Table 8.20 Acromegaly: Oral Proteins / Peptides Pipeline
Table 8.21 Osteoporosis: Current Treatment Options
Table 8.22 Osteoporosis: Side Effects of Current Treatment Options
Table 8.23 Osteoporosis: Oral Proteins / Peptides Pipeline
Table 9.1 Oral Peptides / Proteins: List of Drugs Profiled
Table 9.2 Linzess®: Dosage Details
Table 9.3 Linzess®: Current Status of Development
Table 9.4 Linzess®: Clinical Trials
Table 9.5 Linzess®: Results of Phase III Clinical Trial for CIC
Table 9.6 Ironwood Pharmaceuticals: Key Highlights
Table 9.7 Trulance®: Current Status of Development
Table 9.8 Trulance®: Clinical Trials
Table 9.9 Salix Pharmaceuticals: Key Highlights
Table 9.10 TBRIA™: Current Status of Development
Table 9.11 TBRIA™: Clinical Trials
Table 9.12 TBRIA™: Results of Phase III ORACAL Clinical Trial
Table 9.13 Tarsa Therapeutics: Key Highlights
Table 9.14 Mycapssa®: Current Status of Development
Table 9.15 Mycapssa®: Clinical Trials
Table 9.16 Mycapssa®: Results of Phase III Clinical Trial for Acromegaly
Table 9.17 Chiasma Pharma: Key Highlights
Table 9.18 Drug Profile: ALLN-177
Table 9.19 Drug Profile: INN-202
Table 9.20 Drug Profile: ORMD-0801
Table 9.21 Drug Profile: IN-105
Table 9.22 Drug Profile: Oral HDV Insulin
Table 10.1 Oral Proteins / Peptides: List of Other Associated Drugs
Table 10.2 Minirin®: Generic Versions
Table 10.3 Minirin®: Dosage Details
Table 10.4 Minirin®: Price of Tablets
Table 10.5 Minirin®: Patent Portfolio
Table 10.6 Minirin®: Competitive Landscape
Table 10.7 Sandimmune® / Neoral®: Generic Versions
Table 10.8 Sandimmune® / Neoral®: Dosage Details
Table 10.9 Neoral®: Patent Portfolio
Table 10.10 Sandimmune® / Neoral®: Competitive Landscape
Table 10.11 Sollpura®: Mechanism of Action
Table 10.12 Sollpura®: Current Status of Development
Table 10.13 Sollpura®: Clinical Trials
Table 10.14 Sollpura®: Current Treatment Options
Table 11.1 Oral Protein / Peptide Therapy Development Technologies: Information on Type of Technology, Compatible API Types, Number of Development Programs
Table 11.2 Oral Protein / Peptide Therapy Development Technologies: Information on Target Therapeutic Area and Dosage Form
Table 11.3 Oral Protein / Peptide Therapy Development Technology Developers: Information on Year of Establishment, Employee Count, Company Size and Headquarters
Table 13.1 Oral Delivery Technology Platforms: Comparison of Key Features
Table 13.2 Oral Delivery Technology Platforms: Clinical Stages of Development
Table 13.3 Axcess™ Technology: Oral Proteins / Peptides Pipeline
Table 13.4 Eligen™ Technology: Oral Proteins / Peptides Pipeline
Table 13.5 Entera Technology: Oral Proteins / Peptides Pipeline
Table 13.6 NTRA Oral Delivery Technology: Oral Proteins / Peptides Pipeline
Table 13.7 Peptelligence® Technology: Oral Proteins / Peptides Pipeline
Table 13.8 POD™ Technology: Oral Proteins / Peptides Pipeline
Table 13.9 TPE® Technology: Oral Proteins / Peptides Pipeline
Table 13.10 Uroguanylin Analogue Platform: Oral Proteins / Peptides Pipeline
Table 14.1 Oral Proteins / Peptides: Funding and Investment Analysis
Table 14.2 Oral Proteins / Peptides: Summary of Investments
Table 15.1 Oral Proteins / Peptides: Recent Partnerships
Table 16.1 Oral Proteins / Peptides: List of Publications
Table 18.1 Patent Analysis: CPC Symbols
Table 18.2 Patent Analysis: Most Popular CPC Symbols
Table 18.3 Patent Analysis: List of Top 10 CPC Symbols
Table 18.4 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 18.5 Patent Analysis: List of Relatively Higher Value Patents
Table 20.1 Oral Proteins / Peptides Market: Potential Candidates
Table 20.2 Oral Proteins / Peptides Forecast Assumptions: Price Estimation in Key Geographies
Table 20.3 Oral Proteins / Peptides Forecast Assumptions: Growth Rate Estimation by Key Indications
Table 20.4 Linzess®: Target Patient Population
Table 20.5 Trulance®: Target Patient Population
Table 20.6 Mycapssa®: Target Patient Population
Table 20.7 ALLN-177: Target Patient Population
Table 20.8 Larazotide INN-202: Target Patient Population
Table 20.9 Oral HDV Insulin: Target Patient Population
Table 20.10 ORMD-0801: Target Patient Population
Table 20.11 IN-105: Target Patient Population
Table 21.1 List of Contract Manufacturers Involved in Proteins / Peptides Manufacturing
Table 22.1 Oral Protein / Peptide Therapeutics: Key Commercialization / Lifecycle Management Strategies
Table 25.1 Anthera Pharmaceuticals: Key Highlights
Table 25.2 Carmot Therapeutics: Key Highlights
Table 25.3 IGY Life Sciences and Technology: Key Highlights
Table 25.4 Constant Therapeutics: Key Highlights
Table 26.1 Oral Protein / Peptide Therapeutics: Distribution by Type of Molecule
Table 26.2 Oral Protein / Peptide Therapeutics: Distribution by Phase of Development
Table 26.3 Oral Protein / Peptide Therapeutics: Distribution by Target Therapeutic Area
Table 26.4 Oral Protein / Peptide Therapeutics: Distribution by Biological Target
Table 26.5 Oral Protein / Peptide Therapeutics: Distribution by Mechanism of Action
Table 26.6 Oral Protein / Peptide Therapeutics: Distribution by Phase of Development and Mechanism of Action
Table 26.7 Oral Protein / Peptide Therapeutics: Distribution by Number of Amino Acids
Table 26.8 Key Drug Development Platforms: Distribution by Number of Products
Table 26.9 Oral Protein / Peptide Therapeutics Developers: Distribution by Year of Establishment
Table 26.10 Oral Protein / Peptide Therapeutics Developers: Distribution by Company Size
Table 26.11 Oral Protein / Peptide Therapeutics Developers: Distribution by Location of Headquarters (Region-wise)
Table 26.12 Oral Protein / Peptide Therapeutics Developers: Distribution by Location of Headquarters (Country-wise)
Table 26.13 Oral Protein / Peptide Therapeutics Developers: Distribution by Company Size and Location of Headquarters (Region-wise)
Table 26.14 Most Active Players: Distribution by Number of Pipeline Candidates
Table 26.15 Most Active Players: Distribution by Phase of Development
Table 26.16 KOL Analysis: Distribution by Type of Current Organization
Table 26.17 KOL Analysis: Distribution by Geography
Table 26.18 Linzess®: Historical Sales, 2015-2020 (USD Million)
Table 26.19 Oral Protein / Peptide Development Technologies: Distribution by Type of Technology
Table 26.20 Oral Protein / Peptide Development Technologies: Distribution by Compatible API Types
Table 26.21 Oral Protein / Peptide Development Technologies: Distribution by Target Therapeutic Area
Table 26.22 Oral Protein / Peptide Development Technology Developers: Distribution by Year of Establishment
Table 26.23 Oral Protein / Peptide Development Technology Developers: Distribution by Company Size
Table 26.24 Oral Protein / Peptide Development Technology Developers: Distribution by Location of Headquarters (Region-wise)
Table 26.25 Oral Protein / Peptide Development Technology Developers: Distribution by Location of Headquarters (Country-wise)
Table 26.26 Oral Protein / Peptide Development Technologies: Competitiveness Analysis
Table 26.27 Funding and Investment Analysis: Cumulative Distribution by Number of Funding Instances
Table 26.28 Funding and Investment Analysis: Cumulative Amount Invested (USD Million)
Table 26.29 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 26.30 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 26.31 Funding and Investment Analysis: Summary of Amount Invested
Table 26.32 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested (USD Million)
Table 26.33 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area (USD Million)
Table 26.34 Funding and Investment Analysis: Distribution of Amount Invested by Area of Application (USD Million)
Table 26.35 Funding and Investment Analysis: Distribution of Number of Instances by Target Therapeutic Area
Table 26.36 Funding and Investment Analysis: Distribution of Amount Invested by Target Therapeutic Area (USD Million)
Table 26.37 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 26.38 Funding and Investment Analysis: Regional Distribution by Total Amount Invested (USD Million)
Table 26.39 Most Active Players: Distribution by Number of Instances
Table 26.40 Most Active Players: Distribution by Amount Invested (USD Million)
Table 26.41 Partnerships and Collaborations: Cumulative Year-wise Distribution
Table 26.42 Partnerships and Collaborations: Distribution by Type of Agreement
Table 26.43 Partnerships and Collaborations: Distribution by Area of Application
Table 26.44 Partnerships and Collaborations: Distribution by Type of Partner
Table 26.45 Partnerships and Collaborations: Distribution by Focus Area
Table 26.46 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Table 26.47 Most Active Players: Distribution by Number of Partnerships
Table 26.48 Partnerships and Collaborations: Geographical Distribution
Table 26.49 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 26.50 Publication Analysis: Cumulative Year-wise Trend
Table 26.51 Publication Analysis: Distribution by Type of Molecule
Table 26.52 Publication Analysis: Distribution by Target Therapeutic Area
Table 26.53 Most Prominent Journals: Distribution by Number of Publications
Table 26.54 Most Prominent Authors: Distribution by Number of Publications
Table 26.55 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 26.56 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient population
Table 26.57 Clinical Trial Analysis: Distribution by Trial Status
Table 26.58 Clinical Trial Analysis: Distribution by Trial Phase
Table 26.59 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 26.60 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Phase
Table 26.61 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 26.62 Clinical Trial Analysis: Distribution by Patient Segment
Table 26.63 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 26.64 Clinical Trial Analysis: Distribution by Study Design
Table 26.65 Most Active Industry Players: Distribution by Number of Registered Trials
Table 26.66 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 26.67 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geographical Location
Table 26.68 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geographical Location
Table 26.69 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status
Table 26.70 Patent Analysis: Distribution by Type of Patent
Table 26.71 Patent Analysis: Cumulative Distribution by Publication Year
Table 26.72 Patent Analysis: Distribution by Patent Jurisdiction
Table 26.73 Patent Analysis: Distribution by Legal Status
Table 26.74 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Table 26.75 Leading Industry Players: Distribution by Number of Patents
Table 26.76 Leading Non-Industry Players: Distribution by Number of Patents
Table 26.77 Leading Industry Players: Distribution by International Patents
Table 26.78 Leading Patent Assignees: Distribution by Number of Patents
Table 26.79 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Table 26.80 Patent Analysis: Distribution of Patents by Age
Table 26.81 Oral Protein / Peptide Therapeutics: Patent Valuation
Table 26.82 Overall Oral Proteins / Peptide Therapy Market, 2022-2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.83 Oral Proteins / Peptide Therapy Market: Distribution by Target Disease Indication, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.84 Oral Proteins / Peptide Therapy Market: Distribution by Type of Molecule, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.85 Oral Proteins / Peptide Therapy Market: Distribution by Technology Platforms, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.86 Oral Proteins / Peptide Therapy Market: Distribution by Biological Target, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.87 Oral Proteins / Peptide Therapy Market: Distribution by Mechanism of Action, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.88 Oral Proteins / Peptide Therapy Market: Distribution by Key Players, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.89 Oral Proteins / Peptide Therapy Market: Distribution by Geography 2022 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.90 Linzess® (Ironwood Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Table 26.91 Trulance® (Bausch Health Sciences): Estimated Sales, 2022-2032 (USD Million)
Table 26.92 Mycapssa® (Chiasma): Estimated Sales, 2022-2032 (USD Million)
Table 26.93 ALLN-177 (Allena Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Table 26.94 INN-202 (9 Meters Biopharma): Estimated Sales, 2022-2032 (USD Million)
Table 26.95 Oral HDV Insulin (Diasome Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Table 26.96 ORMD-0801 (Oramed Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
Table 26.97 IN-105 (Biocon): Estimated Sales, 2022-2032 (USD Million)
Table 26.98 Approval Trend for Small Molecule and Large Molecule Drugs (2005-2020)
Table 26.99 Factors for Selecting a CMO Partner
Table 26.100 Protein / Peptide Manufacturers: Distribution by Year of Establishment
Table 26.101 Protein / Peptide Manufacturers: Distribution by Company Size
Table 26.102 Protein / Peptide Manufacturers: Distribution by Location of Headquarters
The following companies / institutes / government bodies and organizations have been mentioned in this report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES